You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究降中生製藥(01177.HK)目標價至4.6元 增長穩固評級「買入」
阿思達克 01-26 09:44
匯豐研究發表研究報告指,中生製藥(01177.HK)的股價年初至今累跌15%,對比同期恆指跌約10%,認爲大部分負面因素已反映在股價之上,考慮到該公司疫苗庫存水平較低,估計減值影響有限,並對其增長前景保持樂觀。 該行預期,在創新藥物銷售將由去年上半年的增長25%,增加快至今年的約30%,推動集團今年收入及盈利增長率達到低雙位數百分比,新藥憧憬陸續獲批將成爲估值潛在正面催化劑,同時全球業務擴張將有助提高利潤,管理層的持續回購亦反映長期增長潛力。 匯豐研究認爲中生製藥增長前景穩固,現價水平爲2024年經調整預測市盈率爲15倍,較同業平均19倍低,估值有吸引力,維持「買入」評級,因應最新估值,將目標價從5元降至4.6元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account